Zobrazeno 1 - 10
of 116
pro vyhledávání: ''
Autor:
Italia Bongarzone, Vera Cappelletti, Maurizio Callari, Maria Grazia Daidone, Valeria Musella, Silvia Veneroni, Barbara Valeri, Loris De Cecco, Marco A. Pierotti
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 409 (2009)
BMC Cancer, Vol 9, Iss 1, p 409 (2009)
Background Gene expression profiling is moving from the research setting to the practical clinical use. Gene signatures able to correctly identify high risk breast cancer patients as well as to predict response to treatment are currently under intens
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Autor:
Gilberto Lopes
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in th
Autor:
Ali Al-Zahrani, Taher Al-Tweigeri, Osama Al Malik, Asma Tulbah, Adher Al-Sayed, Said Dermime, Mohamed Alshabanah, Adnan Ezzat, Naser Elkum, Dahish Ajarim
Publikováno v:
BASE-Bielefeld Academic Search Engine
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
Background Breast cancer in young Saudi women is a crucial problem. According to the 2002 annual report of Saudi National Cancer Registry, breast cancers that developed before the age of 40 comprise 26.4% of all female breast cancers comparing to 6.5
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
Background Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has been associated with lower ca
Autor:
Xue Qin Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
Background Previous studies have documented lower breast cancer survival among women with lower socioeconomic status (SES) in the United States. In this study, I examined the extent to which socioeconomic disparity in breast cancer survival was expla
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho
Autor:
Adrienne Morey, Diana J. Hastrich, David Ingram, Peter C. Willsher, Arlene Chan, Belinda Brown
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
BMC Cancer
BMC Cancer
Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumou
Autor:
Montserrat Rue, Roger Pla, Misericòrdia Carles, J. A. Espinàs, Ester Vilaprinyo, Pilar Brugulat, Montserrat Martínez-Alonso
Publikováno v:
BMC Cancer
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Abierto de la UdL
Universitad de Lleida
Dipòsit Digital de la UB
Universidad de Barcelona
ResearcherID
BMC Cancer, Vol 8, Iss 1, p 336 (2008)
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Abierto de la UdL
Universitad de Lleida
Dipòsit Digital de la UB
Universidad de Barcelona
ResearcherID
BMC Cancer, Vol 8, Iss 1, p 336 (2008)
Background In Catalonia (Spain) breast cancer mortality has declined since the beginning of the 1990s. The dissemination of early detection by mammography and the introduction of adjuvant treatments are among the possible causes of this decrease, and